MTOR and hepatocellular carcinoma: Here, both the PI3K pathway inhibitor LY294002 and the mTOR inhibitor AZD8055 repressed AKT phosphorylation and decreased IL-32 levels (Figure 3A and B), suggesting that AKT activation participates in the regulation of IL-32 expression in HCC cells.